source
- Drugmakers Back US Probe into Germany’s New Drug Pricing PoliciesSeven major pharmaceutical companies, together with industry groups PhRMA and BIO, have urged the German government to amend its recently introduced drug‑pricing reforms. The coalition voiced supp…
- EyePoint’s Phase 3 eye drug falls short of Eylea, stock tumbles 70%EyePoint reported that its experimental treatment for wet age-related macular degeneration did not meet the efficacy endpoints in a Phase 3 trial when compared with the current standard, Eylea. The…